Phase 3 Psychosis Clinical Trials
12 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–12 of 12 trials
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled116 locationsNCT05511363
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled416 locationsNCT05980949
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled20 locationsNCT06947941
Recruiting
Phase 3
Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
Psychosis
Centre Hospitalier St Anne500 enrolled13 locationsNCT05796401
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Phase 3
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Cognitive ImpairmentSchizophrenia; Psychosis
European Group for Research In Schizophrenia171 enrolled16 locationsNCT07084831
Recruiting
Phase 3
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
Early Psychosis
University of California, San Diego120 enrolled2 locationsNCT04411225
Recruiting
Phase 3
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
SchizophreniaApathySchizophrenia; Psychosis
Louisiana State University Health Sciences Center Shreveport80 enrolled1 locationNCT06482554
Not Yet Recruiting
Phase 2Phase 3
Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) effects on perception of illusions, schizotypy and cognition in healthy volunteers
Cannabis use safetySchizophreniaPsychosis
University of Western Australia36 enrolled1 locationACTRN12621000469819
Recruiting
Phase 3
Cannabidiol for At Risk for psychosis Youth
Ultra-High Risk of Psychosis
Orygen405 enrolled1 locationACTRN12621000349842
Completed
Phase 3Phase 4
Seroquel compared to Risperidone in the treatment of psychotic disorders adolescents.
Adolescent psychosis
Dr Harith Swadi60 enrolled1 locationACTRN12605000556640